Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III study of ciclesonide nasal aerosol (74ug and 148ug in the morning) in patients 12 years or older with seasonal allergic rhinitis.

Next Previous
X
Search
Trial Profile

Phase III study of ciclesonide nasal aerosol (74ug and 148ug in the morning) in patients 12 years or older with seasonal allergic rhinitis.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Mar 2013

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ciclesonide (Primary)
  • Indications Seasonal allergic rhinitis
  • Focus Therapeutic Use

    • Most Recent Events

    • 25 Feb 2013 Results from a post-hoc analysis, which included data from this trial, have been presented at the 2013 Annual Meeting of the American Academy of Allergy, Asthma and Immunology according to a Sunovion Pharmaceuticals media release.
    • 28 Nov 2012 New trial record
    • 12 Nov 2012 Results were presented at the 2012 Annual Meeting of the American College of Allergy, Asthma and Immunology (ACAAI), according to a Sunovion Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top